Abstract
As the systemic administration of etoposide is effective in the treatment of relapsed and metastatic brain tumours, a pilot trial was designed to study the feasibility of intraventricular administration of etoposide in such patients. 14 patients aged 2.1 to 33.2 years were treated with intraventricular etoposide simultaneously with either oral or intravenous chemotherapy with trofosfamide or carboplatin and etoposide. In 59 courses (1–12/patient) 0.5 mg etoposide was administered daily via an indwelling subcutaneous reservoir for 5 consecutive days every 2–5 weeks over a period of 0–11 months. During 15 courses in 5 patients serial CSF samples were obtained and etoposide levels were determined by reversed-phase HPLC. Side effects included transient headache and bacterial meningitis, each during 2 courses. Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4±1.2 hours and an AUC of 25.0 ± 9.5 μg h ml–1 (mean ± standard deviation). The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16 l and 0.46 ml min–1 respectively. Intraventricularly administered etoposide is well tolerated. CSF peak levels exceed more than 100-fold those achieved with intravenous infusions. Further studies should be focused on optimizing the dose and schedule and on determining the effectiveness of intraventricularly administered etoposide. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, Reaman G, Steinherz P, Gillespie A and Doherty K (1992) Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 10: 143–148
Bergman I, Pohl CR, Venkataramanan R, Burckart GJ, Stabin M, Barmada MA, Griffin JA and Cheung NK (1999) Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. J Immunother 22: 114–123
Blaney SM, Balis FM and Poplack DG (1991a) Current pharmacological treatment approaches to central nervous system leukemia. Drugs 41: 702–716
Blaney SM, Balis FM and Poplack DG (1991b) Pharmacologic approaches to the treatment of meningeal malignancy. Oncology Huntingt 5: 107–116
Blaney SM, Cole DE, Godwin K, Sung C, Poplack DG and Balis FM (1995) Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 36: 121–124
Blasberg RG, Patlak C and Fenstermacher JD (1975) Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 73–83
Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E and Kim S (1993) Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 50: 261–264
Chamberlain MC, Kormanik PA and Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87: 694–699
Chamberlain MC, Kormanik P, Jaeckle KA and Glantz M (1999) 111-Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 52: 216–217
Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH, Bostrom BC, Goldman S, Sender LS, Gardner SL, Li H, Allen JC and Finlay JL (1998) High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 16: 222–228
Farina P, Marzillo G and D'Incalci M (1981) High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyraniso-dase) (VP16-213) in human plasma. J Chromatogr 222: 141–145
Grossman SA and Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103–119
Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA and Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44: 379–382
Henwood JM and Brogden RN (1990) Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438–490
Kiya K, Uozumi T, Ogasawara H, Sugiyama K, Hotta T, Mikami T and Kurisu K (1992) Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 29: 339–342
Kleihues P, Burger PC and Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3: 255–268
Kuehl J, Berthold F, Bode U, Bucsky P, Graf N, Grel A, Maass E, Bamberg M, Kaatsch P, Kleihus P, Rating D, Riehm H and Soerenson N (1993) Preradiation chemotherapy of children with poor prognosis medulloblastoma. Am J Pediatr Hematol Oncol 15 (suppl A): 67–71
Kuehl J, Mueller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, Graf N, Gnekow A, Scheurlen W, Goebel U, Wolff JE, Bamberg M, Kaatsch P, Kleihues P, Rating D, Soerensen N and Wiestler OD (1998) Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT '88/' 89. Klin Paediatr 210: 227–233
Nakagawa H, Yamada M, Fukushima M and Ikenaka K (1999) Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmacol 43: 247–256
Perek D, Perek-Polnik M and Drogosiewicz M (1999) Pattern of relapse and outcome following recurrence of disease in 105 patients with MB/PNET. Med Pediatr Oncol 33: 290
Postmus PE, Holthuis JJ, Haaxma RH, Mulder NH, Vencken LM, van Oort WJ, Sleijfer DT and Sluiter HJ (1984) Penetration of VP 16–213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 2: 215–220
Relling MV, Mahmoud HH, Pui CH, Sandlund JT, Rivera GK, Ribeiro RC, Crist WM and Evans WE (1996) Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 14: 399–404
Rubinstein LJ, Herman MM, Long TF and Wilbur JR (1975) Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35: 291–305
Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD and Friedman HS (1999) Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 5: 1183–1188
Savaraj N, Feun LG, Lu K, Gray K, Wang C and Loo TL (1992) Pharmacology of intrathecal VP-16-213 in dogs. J Neurooncol 13: 211–215
Schmandt S and Kuehl J (1998) Chemotherapy as prophylaxis and treatment of meningeosis in children less than 3 years of age with medulloblastoma. J Neurooncol 38: 187–192
Slavc I, Schuller E, Czech T, Hainfellner JA, Seidl R and Dieckmann K (1998) Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 38: 213–218
Slavc I, Gulesserian T, Flager J, Guenes M, Schuller E, Czech T and Dieckmann K (2000) Feasibility of long-term intraventricular therapy with mafosfamide (n=22) and VP-16 (n=7) in 22 heavily pretreated and irradiated pediatric brain tumor patients. Neuro-Oncology 2: S92
Stremetzne S, Jaehde U and Schunack W (1997) Determination of the cytotoxic catechol metabolite of etoposide (3′O-demethyletoposide) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 703: 209–215
Tomlinson FH, Lihou MG and Smith PJ (1991) Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas. Br J Cancer 64: 1051–1059
Van der Gaast A, Sonneveld P, Mans DR and Splinter TA (1992) Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother Pharmacol 29: 335–337
World Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO Offset Publication 48: 1–41
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fleischhack, G., Reif, S., Hasan, C. et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 84, 1453–1459 (2001). https://doi.org/10.1054/bjoc.2001.1841
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1841
Keywords
This article is cited by
-
Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours
Child's Nervous System (2023)
-
Infusion of etoposide in the CA1 disrupts hippocampal immediate early gene expression and hippocampus-dependent learning
Scientific Reports (2022)
-
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia
Current Hematologic Malignancy Reports (2022)
-
A decision process for drug discovery in retinoblastoma
Investigational New Drugs (2021)
-
Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors
Journal of Neuro-Oncology (2016)